Villegas VCA, Ramírez PDM

Language: Spanish
References: 42
Page: 5-17
PDF size: 249.05 Kb.

ABSTRACT

Nowadays there are two accepted theories explaining the origin and development of the cancer: Tumor Immunoediting and the inflammation associated to the cancer. In both, the participation of regulatory T cells (Treg) in the carcinogenesis, progression and metastatic processes is evident but most of the studies locate these cells in advanced stages of the immunopathogenesis of the neoplastic process. However, these cells participate in the peripheral tolerance and homeostasis of the immune system. Therefore their role is not limited to contribute in the tumor cell evasion, but rather they may participate before the first cancer cell emerges. Their most important function is probably the one involved in the equilibrium stage of the immunoediting, because in this phase the adaptive immune system is decisive for the progression into the escape stage, being able in some cases to induce a spontaneous regression of the tumor. A study in depth of the dynamics of these cells in the initial stages of the cancer can help with the identification of biomarkers for diagnosis and prognosis, as well as therapeutic targets that could change the course of cancer. In this revision an approach to the participation of the Treg in the development of cancer through inflammation and immunoediting is described.

REFERENCES

1. Siachoque H, Satisteban N, Iglesias Gamarra A. Linfocitos T reguladores: subpoblaciones, mecanismo de acción e importancia en el control de la autoinmunidad. Rev Colomb Reumatol. 2011;18(3):203-20.

2. Beltran Garate B. Rol de las células T reguladoras en cáncer. Rev Fac med Hum. 2008;8(1):58-60.

3. Gershon K, Kondo K. Cell interactions in the induction of tolerance: the role of thymic lymphocytes. Immunology. 1970;18:723.

4. Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25).Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol. 1995;155:1151-64.

5. Miyara M, Yoshioka Y, Kitoh A, Shima T, Wing K, Niwa A, et al. Functional delineation and differentiation dynamics of human CD4+ T Cells expressing the FoxP3 transcription factor. Immunity. 2009;30:899-911.

6. Cosmi L, Liotta F, Lazzeri E, et al. Human CD8+ CD25+ thymocytes share phenotypic and functional features with CD4+ CD 25 + regulatory thymocytes. Blood. 2003;102: 4107-14.

7. Sharafieh R, Lemire Y, Powell S, et al. Immune amplification of murine CD8 suppressor T cells induced via an immune-privileged site: quantifying suppressor T cells functionally. PLoS One. 2011;6:e22496.

8. Liu L, Lan Q, Lu L, Chen M, Xia Z, Ma J, et al. Phenotypic and functional characteristic of a newly identified CD8+ Foxp3- CD103+ regulatory T cells. J Mol Cell Biol. 2013;6:81-92.

9. Coley WB. The treatment of malignant tumors by repeated inoculations of erysipelas: with a report of ten original cases. Am J Med Sci. 1898;105:487-511.

10. Grivennikov SI, Greten FR, Karin M. Immunity, Inflammation, and Cancer. Cell. 2010;140:883-899.

11. Smith MJ, Godfrey DI, Trapani JA. A fresh look at tumor immune surveillance and immunotherapy. Nature Immunology. 2001;4:293-9.

12. Schreiber RD, Old LJ, Smyth MJ. Cancer Immunoediting: Integrating Immunity’s Rolesin Cancer. Science. 2011;331:1565-70.

13. Hanahan D, Coussens LM. Accessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment. Cancer Cell. 2012;21:309-22.

14. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. 2004 [citado: 7 enero 2014]. Disponible en: http:// www.nature.com/naturemedicine/10.1038/nm1093.

15. Wing K, Fehervari Z, Sakaguchi S. Emerging possibilities in the development and function of regulatory T cells. Int Immunol. 2006; 18(7):991-1000.

16. Curotto de Lafaille MA, Lafaille JJ. Natural and Adaptive Foxp3+ Regulatory T

17. Cells: More of the Same or a Division of Labor? Immunity. 2009;30:626-35.

18. Horwitz, D.A., Zheng, S.G., and Gray, J.D. Natural and TGF-beta-induced Foxp3+ CD4+ CD 25+ regulatory T cells are not mirror images of each other. Trends Immunol. 2008;29:429-35.

19. Josefowicz SZ, Lu LF, Rudensky AY. Regulatory T Cells: Mechanisms of Differentiation and Function. Annu Rev Immunol. 2012;30:531-64.

20. Bilate AM, Lafaille JJ. Induced CD4+ Foxp3+ Regulatory T Cells in Immune Tolerance. Annu Rev Immunol. 2012;30:733-58.

21. Miyara M, Sakaguchi S. Human FoxP3+ CD4+ regulatory T cells: their knowns and unknowns. Immunol Cell Biol. 2011;89:346-51.

22. Sakaguchi S, Miyara M, Costantino CM, Hafler DA. FOXP3+ regulatory T cells in the human immune system. Nature Rev Immunol. 2010;10:490-500.

23. Wing K, Onishi Y, Prieto-Martin P, Yamaguchi T, Miyara M, Fehervari Z, et al. CTLA-4 Control over Foxp3+ Regulatory T Cell Function. Science. 2008;322:271-5.

24. Wing JB, Sakaguchi S. Multiple Treg suppressive modules and their adaptability. Front Immunol. 2012;3:1-6.

25. Sakaguchi S, Wing K, Onishi Y, Prieto-Martin P, Yamaguchi T. Regulatory T cells: how do they suppress immune responses? Int Immunol. 2009;21(10):1105-11.

26. Vignali DA, Collison LW, Workman CJ. How regulatory T cells work. Nature Rev Immunol. 2008;8:523-32.

27. Li MO, Wan YY, Flavell RA. T Cell-Produced Transforming Growth Factor-β1controls T Cell tolerance and regulates Th1- and Th17- Cell differentiation. Immunity. 2007;26:579-91.

28. Maynard CL, Harrington LE, Janowski KM, Oliver JR, Zindl CL, Rudensky AY, et al. Regulatory T cells expressing interleukin 10 develop from Foxp3+ and Foxp3-precursor cells in the absence of interleukin 10. Nat Immunol. 2007;8(9):931-41.

29. Rubtsov YP, Rasmussen JP, Chi EY, Fontenot J, Castelli L, Ye X, et al. Regulatory T Cell-Derived Interleukin-10 Limits Inflammation at Environmental Interfaces. Immunity. 2008;28:546-58.

30. Vesely MD, Kershaw MH, Schreiber RD, Smyth MJ. Natural Innate and Adaptive Immunity to Cancer. Annu Rev Immunol. 2011;29:235-71.

31. Portaa C, Larghib P, Rimoldic M, Totarob MG, Allavenac P, Mantovanic A, et al. Cellular and molecular pathways linking inflammation and cancer. Immunobiology. 2009; 214:761-77.

32. Colotta F, Allavena P, Sica A, Garlanda C, Mantovanic A. Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis. 2009; 30(7):1073-81.

33. Harty JT, Badovinac VP. Shaping and reshaping CD8+ T cell memory. Nat Rev Immunol. 2008;8:107-19.

34. Suffia IJ, Reckling SK, Piccirillo CA, Goldszmid RS, Belkaid Y. Infected site restricted Foxp3+ natural regulatory T cells are specific for microbial antigens. J Exp Med. 2006;203:777-88.

35. Sutmuller R, Garritsen A, Adema GJ. Regulatory T cells and toll-like receptors: regulating the regulators. Ann Rheum Dis. 2007;66(Suppl):91-5.

36. Ahlers JD, Belyakov IM. Memories that last forever: strategies for optimizing vaccine T cell memory. Blood. 2010; 115(9):1678-89.

37. Fridman WH, Pagès F, Sautès-Fridman C, Galon J. The immune contexture in human tumors: impact on clinical outcome. Nat Rev Cancer. 2012;12:298-306.

38. Hyun-Tak J, Yun Hee J, Hyo Jin P, Sang-Jun H. Mechanism of T cell exhaustion in a chronic environment. BMB Reports. 2011;44:217-31.

39. Adeegbe DO, Nishikawa H. Natural and induced T regulatory cells in cancer. Front Immunol. 2013;4:1-14.

40. Nishikawa H, Sakaguchi S. Regulatory T cells in cancer immunotherapy. Curr Opinin Immunol. 2014;27:1-7.

41. Oleinika K, Nibbs RJ, Graham GJ, Fraser AR. Suppression, subversion and escape: the role of regulatory T cells in cancer progression. Clin Exp Immunol. 2012;171:36-45.

42. Klinker MW, Lundy SK. Multiple Mechanisms of Immune Suppression by B Lymphocytes. Mol Med. 2012;18: 123-137.